225 related articles for article (PubMed ID: 22743624)
21. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
Sekeres MA; Watts J; Radinoff A; Sangerman MA; Cerrano M; Lopez PF; Zeidner JF; Campelo MD; Graux C; Liesveld J; Selleslag D; Tzvetkov N; Fram RJ; Zhao D; Bell J; Friedlander S; Faller DV; Adès L
Leukemia; 2021 Jul; 35(7):2119-2124. PubMed ID: 33483617
[No Abstract] [Full Text] [Related]
22. Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine.
Shabanova I; Cada M; Johnston DL; Abbott LS; Leung EW; Schechter T; Dror Y; Klaassen RJ
J Pediatr Hematol Oncol; 2020 Apr; 42(3):170-174. PubMed ID: 32134844
[TBL] [Abstract][Full Text] [Related]
23. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
[TBL] [Abstract][Full Text] [Related]
24. Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.
Adès L; Itzykson R; Fenaux P
Semin Hematol; 2012 Oct; 49(4):323-9. PubMed ID: 23079062
[TBL] [Abstract][Full Text] [Related]
25. 5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.
Curik N; Burda P; Vargova K; Pospisil V; Belickova M; Vlckova P; Savvulidi F; Necas E; Hajkova H; Haskovec C; Cermak J; Krivjanska M; Trneny M; Laslo P; Jonasova A; Stopka T
Leukemia; 2012 Aug; 26(8):1804-11. PubMed ID: 22343522
[TBL] [Abstract][Full Text] [Related]
26. Atypical presentations of Sweet's syndrome in patients with MDS/AML receiving combinations of hypomethylating agents with histone deacetylase inhibitors.
Alencar C; Abramowtiz M; Parekh S; Braunshweig I; Jacobson M; Silverman L; Verma A
Am J Hematol; 2009 Oct; 84(10):688-9. PubMed ID: 19722261
[No Abstract] [Full Text] [Related]
27. [5-day decitabine for treatment of myelodysplastic syndromes with complex karyotype abnormalities and acute myeloid leukemia].
Gao S; Hu XH; Qiu HY; Xu Y; Jin ZM; He GS; Tang XW; Han Y; Chen SN; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):542-3. PubMed ID: 23827117
[No Abstract] [Full Text] [Related]
28. Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.
Subari S; Baidoun F; Hreh M; Patnaik M; Hashmi S; Elliott M; Hogan W; Litzow M; Al-Kali A
Int J Hematol; 2016 Apr; 103(4):409-15. PubMed ID: 26781617
[TBL] [Abstract][Full Text] [Related]
29. Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine.
Breccia M; Fianchi L; Lunghi M; Gaidano G; Levis A; Finelli C; Santini V; Musto P; Mansueto G; Oliva EN; Leoni P; Spiriti MA; Hohaus S; Leone G; Alimena G; Voso MT
Leuk Lymphoma; 2013 Aug; 54(8):1786-7. PubMed ID: 23151268
[No Abstract] [Full Text] [Related]
30. Epigenetic control of NF-κB-dependent FAS gene transcription during progression of myelodysplastic syndromes.
Ettou S; Humbrecht C; Benet B; Billot K; d'Allard D; Mariot V; Goodhardt M; Kosmider O; Mayeux P; Solary E; Fontenay M
Mol Cancer Res; 2013 Jul; 11(7):724-35. PubMed ID: 23604035
[TBL] [Abstract][Full Text] [Related]
31. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.
Santini V
Expert Rev Hematol; 2009 Apr; 2(2):121-7. PubMed ID: 21083445
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of GYS1, MIF, and MYC is associated with adverse outcome and poor response to azacitidine in myelodysplastic syndromes and acute myeloid leukemia.
Falantes JF; Trujillo P; Piruat JI; Calderón C; Márquez-Malaver FJ; Martín-Antonio B; Millán A; Gómez M; González J; Martino ML; Montero I; Parody R; Espigado I; Urbano-Ispizua A; Pérez-Simón JA
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):236-44. PubMed ID: 25487600
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML.
Tenti E; Papayannidis C; Marconi G; Parisi S; Simonetti G; Paolini S; Sartor C; Ottaviani E; Testoni N; Martinelli G
Expert Opin Pharmacother; 2016 Dec; 17(18):2479-2486. PubMed ID: 27829292
[TBL] [Abstract][Full Text] [Related]
34. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Daver N; Boddu P; Garcia-Manero G; Yadav SS; Sharma P; Allison J; Kantarjian H
Leukemia; 2018 May; 32(5):1094-1105. PubMed ID: 29487386
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of the Fibrinogen-Albumin Ratio Index in patients with myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes treated with azacitidine.
Akimoto M; Sakurai A; Nishiyama-Fujita Y; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2021 Apr; 100(4):953-957. PubMed ID: 33521864
[TBL] [Abstract][Full Text] [Related]
36. Azacitidine access program for Belgian patients with myelodysplastic syndromes, acute myeloid leukemia or chronic myelomonocytic leukemia.
Meers S; Selleslag D; Potier H; Glasmacher A; Mineur P; Voelter V
Curr Med Res Opin; 2015 Jan; 31(1):35-42. PubMed ID: 25317956
[TBL] [Abstract][Full Text] [Related]
37. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
38. Effectiveness and safety of different azacitidine dosage regimens in patients with myelodysplastic syndromes or acute myeloid leukemia.
García-Delgado R; de Miguel D; Bailén A; González JR; Bargay J; Falantes JF; Andreu R; Ramos F; Tormo M; Brunet S; Figueredo A; Casaño J; Medina A; Badiella L; Jurado AF; Sanz G
Leuk Res; 2014 Jul; 38(7):744-50. PubMed ID: 24795069
[TBL] [Abstract][Full Text] [Related]
39. The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the "Rete Ematologica Lombarda".
Molteni A; Riva M; Borin L; Bernardi M; Pelizzari AM; Freyrie A; Della Porta M; Nichelatti M; Ravano E; Quaresmini G; Mariotti J; Caramazza D; Ubezio M; Guarco S; Gigli F; Greco R; Cairoli R; Morra E
Leuk Res; 2016 Mar; 42():21-7. PubMed ID: 26852003
[TBL] [Abstract][Full Text] [Related]
40. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
Follo MY; Finelli C; Mongiorgi S; Clissa C; Chiarini F; Ramazzotti G; Paolini S; Martinelli G; Martelli AM; Cocco L
Leukemia; 2011 Feb; 25(2):271-80. PubMed ID: 21109771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
